To explore the effect of the intervention of clinical pharmacists on the rational use of potassium magnesium aspartate . Methods:The prescriptions of outpatients in the fourth quarter of 2013 and those of emergency in the second quarter of 2014 with potassium magnesium aspartate injection were collected and analyzed. The unreasonable use rate of the drug before and after the intervention was compared. Results:The unreasonable use rate of potassium magnesium aspartate before the intervention was 35. 4%, that after the intervention was 15. 8%, and the difference was statistically significant(P<0. 01) . The difference in beyond the indica-tion, high concentration and unreasonable compatibility of the drug before and after the intervention was statistically significant ( P<0. 01 or P<0. 05) . Conclusion: The intervention of clinical pharmacists in the use of potassium magnesium aspartate is effective, which should be performed continuously.

0.05). The incidence of restenosis and major adverse cardiovascular events were significantly less in the hyperbaric oxygen group than that in the control group (6.67% vs 22.58% for restenosis, and 8.82% vs 38.24% for major adverse cardiovascular events; P0.05). No severe adverse effect was found during hyperbaric oxygen therapy in the hyperbaric oxygen group. Conclusion Hyperbaric oxygen therapy is effective and safe in preventing restenosis after intracoronary stenting.